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Summary Targeting angiogenesis is a valid anti-cancer
strategy. Aflibercept is designed to sequester circulating
vascular endothelial growth factor (VEGF) by preventing
VEGF from binding to its receptors. This phase I study was
to evaluate a new formulation of subcutaneously adminis-
tered aflibercept in patients with advanced solid tumors.
Here we report our experience with the toxicity, pharma-
cokinetic profile and efficacy of the new 100 mg/mL
subcutaneous (SC) formulation of aflibercept administered
at a dose of at 4 mg/kg every 2 weeks.
Introduction
Angiogenesis is a hallmark for tumorigenesis [1], and
vascular endothelial growth factor (VEGF) is a crucial
mediator for this process. VEGF binds to its receptors,
VEGF receptor 1 (VEGFR1) and VEGF receptor 2
(VEGFR2) to trigger cell proliferation, migration and
metastasis [2, 3]. Agents blocking the VEGF axis have
been successfully used as anti-cancer therapies.
Among various approaches to targeting angiogenesis,
inhibiting VEGF ligand and receptor interactions has been
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the most successful [4]. To prevent VEGF from binding to its
receptors, aflibercept (VEGF Trap; Regeneron Pharmaceuti-
cal and Sanofi-Aventis Pharmaceuticals) was developed for
sequestering circulating VEGF. Aflibercept is a soluble
protein that fuses the second immunoglobulin (Ig) domain
of the VEGFR1 and the third Ig domain of the VEGFR2 to
the Fc domain of human Ig G1 [5]. Antitumor activities of
aflibercept have been demonstrated in preclinical studies and
in recent clinical trials [6–14]. In clinical studies, aflibercept
has been administered via an intravenous (IV) or subcutane-
ous (SC) route. Tew et al reported a phase I study using an
aflibercept SC formulation of 25 mg/mL in patients with
refractory solid tumors. In that study, the maximum tolerated
dose (MTD) of aflibercept was not reached due to the
volume of the drug to be administered via the SC route [12].
To achieve the SC administration of a higher dose of
aflibercept, a new formulation of 100 mg/mL was generated
and tested along with the IV formulation in a separate phase I
study. It was determined that the SC dose should be 4 mg/kg
every 2 weeks because of the similar bioavailability of
aflibercept via the SC and IV routes. Lockhart et al reported
on the toxicity data, pharmacokinetic profile and efficacy
results of the IV formulation of aflibercept , and a dose of
4 mg/kg administered every 2 weeks was recommended for
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further phase II or III trials [11]. Here, we report our
experience with the toxicity, pharmacokinetic profile and
efficacy of the new 100 mg/mL SC formulation of aflibercept
administered SC at 4 mg/kg every 2 weeks.
Methods
Eligibility The study was a phase I clinical trial evaluating
aflibercept IV and SC formulations in patients with
refractory solid tumors at Vanderbilt University Medical
Center and Memorial Sloan-Kettering Cancer Center.
Results from the IV cohort have been published previously.
The same eligibility criteria were used for the IV and SC
cohorts, and were reported previously [11].
Drug dosage and administration Lyophilized aflibercept
(200 mg) in a 20-mL glass vial was reconstituted under sterile
conditions by addition of 2.3 mL water for SC injection to
ultimately produce a concentration of 100 mg/mL. Aflibercept
was stored at 2–8oC. Aflibercept 4.0 mg/kg was administered
SC every 2 weeks using a 0.3 or 1.0 mL syringe with a fixed
29-gauge needle. Dose reduction to 3.0 mg/kg and/or
2.0 mg/kg was allowed for protocol specified toxicity. The
body sites for injections were rotated between the anterior
abdominal wall, the deltoid region and the anterior thigh. To
ensure uniformity of drug absorption, all patients received
the first injection to the anterior abdominal wall.
Pharmacokinetics Plasma samples were drawn after each
drug administration. Plasma concentrations of free aflibercept
and aflibercept: VEGF complexes (“bound aflibercept”) were
measured by direct enzyme-linked immunosorbent assay
(ELISA) methods, as previously published [11]. The limits
of quantitation of free aflibercept and bound aflibercept were
31 ng/mL and 44 ng/mL, respectively.
Immunogenicity Immunogenicity testing was performed by
measuring the presence of anti-aflibercept antibodies via
ELISA 2 months after the last dose of aflibercept.
Toxicity and efficacy Patients were observed on a regular
basis for toxicities which were graded by the National
Cancer institute Common Terminology Criteria for Adverse
Events (version 3.0). Dose limiting toxicity (DLT) was
defined previously [11]. Tumor response was assessed by
RECIST criteria every two cycles by magnetic resonance
imaging (MRI) or computed tomography (CT). Patients
continued in the study until disease progression, unaccept-
able toxicity or consent withdrawal occurred.
Statistical methods Descriptive statistics including median,
minimum, maximum and percentage were used in this study.
Results
Demographic information A total of 13 patients were
screened for the SC cohort; 10 patients were enrolled and
received 4 mg/kg of aflibercept every 2 weeks. Demographic
data are listed in Table 1. The median age for the cohort was
58 years. Of the 10 patients receiving 4 mg/kg every
2 weeks, 8 were female. Five out of the 10 patients had
ovarian cancer as their primary tumors. The median number
of prior regimens was 2.5. Median treatment duration was
30 days with the maximal duration being 184 days. Two of
the 10 patients received 11–13 doses of aflibercept.
Toxicity The safety-evaluable population was defined as
patients who received at least one dose of aflibercept.
Among 10 patients treated at 4 mg/kg every 2 weeks, 9
patients (90%) experienced a treatment-emergent event that
was possibly related to aflibercept. Most toxicities were
grade 2 or less and resolved upon drug discontinuation. The
common toxicities attributed to aflibercept at 4 mg/kg every























Min: Max 15: 184
Number of doses administered
2 Doses 3 (30.0%)
4 Doses 4 (40.0%)
6–10 Doses 1 (10.0%)
11–13 Doses 2 (20.0%)
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2 weeks were fatigue, dysphonia, hypertension, nausea,
myalgia, and arthralgia (Table 2). Two patients experienced
severe adverse events (SAE) (hypertension and abdominal
pain) possibly related to aflibercept. Among the patients
taking SC aflibercept, no deaths designated as possibly related
to the drug were observed, and no patients were discontinued
from the study due to treatment-related toxicity.
We examined toxicities possibly related to inhibition of
VEGF. Hypertension was seen in 5 out of 10 patients with
one subject experiencing grade 3 hypertension. The same
subject also developed grade 1 proteinuria, as confirmed by
24 h urine collection. No grade 3 or 4 proteinuria events
were observed.
Pharmacokinetics (PK) PK data of SC aflibercept at 4 mg/kg
every 2 weeks were collected from 7 patients who had
received at least 2 doses of aflibercept and completed by Day
22 . At the steady state, the mean plasma concentrations of the
free aflibercept and bound aflibercept were 8.69 μg/mL and
4.49 μg/mL, respectively (Fig. 1). The free/bound ratios at
steady state was 1.74, indicating an excess of free over
bound aflibercept at SC dose levels of 4.0 mg/kg every
2 weeks. The PK profiles from patients receiving SC
aflibercept fell into two distinct populations. The first group
demonstrated a PK profile with a Cmax around 20 μg/mL
and t 1/2 ranging between 7 and 9 days, while the second
group showed a Cmax rround 3–5 μg/mL. The bound
aflibercept exposure in the first group is higher than the
second group.
Immunogenicity Anti-aflibercept antibodies were not
detected in any patients.
Table 2 Common adverse events and severe adverse events (Grade 3/4)
possibly related to aflibercept SC 4 mg/kg
Adverse Event Patients (N=10)
All Grade Grade 3/4
No. % No. %
General disorder and administration site 7 (70%) –
Fatigue 7 (70%) –
Early satiety 1 (10%) –




Arthralgia 4 (40%) –
Myalgia 4 (40%) –
Back pain 2 (20%) –
Joint stiffness 1 (10%) –
Muscle spasms 1 (10%) –
Muscular weakness 1 (10%) –
Musculoskeletal pain 1 (10%) –
Pain in extremity 1 (10%) –
Respiratory, thoracic and mediastinal
disorders
7 (70%) –
Dysphonia 7 (70%) –
Nasal dryness 2 (20%) –
Dyspnea 1 (10%) –
Dyspnea on exertion 1 (10%) –
Nasal congestion 1 (10%) –
Cough 1 (10%) –
Pharyngolaryngeal pain 1 (10%) –
Gastrointestinal disorders 5 (50%) –
Nausea 4 (40%) –
Constipation 2 (20%) –
Abdominal pain 1 (10%) –
Diarrhea 1 (10%) –
Glossodynia 1 (10%) –
Oral pain 1 (10%) –
*Vascular disorder 5 (50%) 1 (10%)
Hypertension 5 (50%) 1 (10%)
Metabolism and nutrition disorder 4 (40%) –
Anorexia 2 (20%) –
Decreased appetite 2 (20%) –
Skin and subcutaneous tissue disorder 4 (40%) –
Rash 3 (30%) –
Dry skin 2 (20%) –
Erythema 1 (10%) –
Nail disorder 1 (10%) –
Onychoclasis 1 (10%) –
Nervous system disorder 3 (30%) –
Headache 3 (30%) –
*Renal and urinary disorder 1 (10%) –
Proteinuria 1 (10%) –
Common adverse event is defined by that the frequency of the adverse
event of all grades in that class is 15% or greater
* Typical side effects associated with the angiogenesis inhibitors
Fig. 1 Mean free and bound aflibercept SC (n=7) and IV (n=6) at
4 mg/kg concentration at steady state
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Efficacy Treatment efficacy was assessed in 5 patients who
received at least one dose of aflibercept and had at least one
post baseline assessment. Among 5 evaluable patients, 2
demonstrated stable disease. A 69-year-old woman with
papillary serous carcinoma of the ovary had stable disease
for 203 days. She was previously treated with multiple lines
of chemotherapy including carboplatin, paclitaxel, liposo-
mal doxorubicin, gemcitabine, and topotecan. The second
patient was a 58-year-old woman with granulosa cell tumor
of the ovary, and she had stable disease for 50 days. Three
out of 5 had disease progression.
Discussion
Targeting angiogenesis is a mainstream anti-cancer therapy.
The benefit of depleting of VEGF by aflibercept has been
demonstrated in preclinical studies and early phase clinical
trials [6–14]. Currently, multiple Phase III clinical trials
using the aflibercept IV formulation in combination with
other agents are ongoing. A dose of 4 mg/kg administered
IV every 2 weeks has been recommended for future clinical
trials [11].
Here, we report the toxicity, PK data and efficacy of the new
SC formulation of aflibercept at 100 mg/mL from a phase I
study. The sample size of 10 patients is adequate to assess
toxicity of the new formulation, and the toxicities were found
to be tolerable and reversible. Hypertension of any grade was
seen in 5 patients (50%) in the SC group, compared with 5
(71.4%) out of 7 patients receiving intravenous aflibercept at
4 mg/kg [11]. Moreover, grade 3 and 4 hypertension was seen
in 1 (10%) out of 10 patients receiving SC aflibercept,
compared with 3 (42.9%) out of 7 patients receiving IV
aflibercept. Grade 3 and 4 proteinuria possibly related to
aflibercept were see in 1 out 10 SC patients and 1 out 7 IV
patients, respectively. PK data of aflibercept suggest adequate
depletion of free circulating VEGF. At steady state, plasma
concentrations of free aflibercept were higher than bound
aflibercept indicating maximum ligand blockade and were
generally similar to IV aflibercept administered at the same
dose. Furthermore, the mechanisms contributing to two
distinct PK profiles of SC aflibercept need to be further
explored. Tumor control (stable disease) was seen in two out
of five evaluable patients.
For future development, the SC route of aflibercept
delivery may provide advantages over IV formulations,
including time and resource conservation. SC administration
may allow self-administration by patients at home, sparing the
need for intravenous access, for specialized nursing care and a
reduction in visits to the physician’s office. Based on our
study, further investigation of SC aflibercept in combination
with chemotherapy is warranted.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Hanahan D, Weinberg RA (2011) The hallmarks of cancer: the
next generation. Cell 144:646–674
2. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms
of anti-tumour activity. Nat Rev Cancer 8:579–591
3. Jain RK (2003) Molecular regulation of vessel maturation. Nat
Med 9:685–693
4. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA,
Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E et al
(2001) Comparative evaluation of the antitumor activity of
antiangiogenic proteins delivered by gene transfer. Proc Natl
Acad Sci U S A 98:4605–4610
5. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M,
Boland P, Leidich R, Hylton D, Burova E et al (2002) VEGF-trap:
a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci
U S A 99:11393–11398
6. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI,
Yancopoulos GD, Jaffe RB (2003) Vascular endothelial growth
factor-trap decreases tumor burden, inhibits ascites, and causes
dramatic vascular remodeling in an ovarian cancer model. Clin
Cancer Res 9:5721–5728
7. Fukasawa M, Korc M (2004) Vascular endothelial growth factor-
trap suppresses tumorigenicity of multiple pancreatic cancer cell
lines. Clin Cancer Res 10:3327–3332
8. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe
RB (2005) Vascular endothelial growth factor trap combined with
paclitaxel strikingly inhibits tumor and ascites, prolonging
survival in a human ovarian cancer model. Clin Cancer Res
11:6966–6971
9. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW,
Frischer JS, Soffer SZ, Ring L, New T, Zabski S et al (2002)
Potent VEGF blockade causes regression of coopted vessels in a
model of neuroblastoma. Proc Natl Acad Sci U S A 99:11399–
11404
10. Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E,
Gabrail N, Hart LL, Albain KS, Berkowitz L et al (2010) A
multicenter, phase 2 study of vascular endothelial growth factor
trap (Aflibercept) in platinum- and erlotinib-resistant adenocarci-
noma of the lung. J Thorac Oncol 5:1054–1059
11. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P,
Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH et al
(2010) Phase I study of intravenous vascular endothelial growth
factor trap, aflibercept, in patients with advanced solid tumors. J
Clin Oncol 28:207-214
12. Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian
C, Sabbatini P, Mendelson D, Schwartz L, Gettinger S et al (2010)
Phase 1 study of aflibercept administered subcutaneously to
patients with advanced solid tumors. Clin Cancer Res 16:358–
366
13. Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides
B, Qian DZ, Yancopoulos GD, Pili R (2007) Vascular endothelial
growth factor trap blocks tumor growth, metastasis formation, and
vascular leakage in an orthotopic murine renal cell cancer model.
Clin Cancer Res 13:4201–4208
14. Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C,
Holash J, Yancopoulos GD, Dicker AP (2007) VEGF trap in
combination with radiotherapy improves tumor control in u87
glioblastoma. Int J Radiat Oncol Biol Phys 67:1526–1537
Invest New Drugs (2012) 30:1958–1961 1961
